



HAL
open science

Semisynthetic Pneumococcal Glycoconjugate Nanovaccine

Maruthi Prasanna, Rubén Varela Calvino, Annie Lambert, Maria Arista
Romero, Sylvia Pujals, François Trottein, Emilie Camberlein, Cyrille
Grandjean, Noemi Csaba

► **To cite this version:**

Maruthi Prasanna, Rubén Varela Calvino, Annie Lambert, Maria Arista Romero, Sylvia Pujals, et al.. Semisynthetic Pneumococcal Glycoconjugate Nanovaccine. *Bioconjugate Chemistry*, 2023, 34 (9), pp.1563-1575. 10.1021/acs.bioconjchem.3c00252 . hal-04209406

HAL Id: hal-04209406

<https://hal.science/hal-04209406>

Submitted on 18 Sep 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

Semisynthetic Pneumococcal Glycoconjugate Nanovaccine

Maruthi Prasanna, Rubén Varela Calvino, Annie Lambert, Maria Arista Romero, Sylvia Pujals, François Trottein, Emilie Camberlein, Cyrille Grandjean,* and Noemi Csaba*

Cite This: <https://doi.org/10.1021/acs.bioconjchem.3c00252>

Read Online


ACCESS |

Metrics & More

Article Recommendations

Supporting Information

ABSTRACT: Pneumococcal conjugate vaccines offer an excellent safety profile and high protection against the serotypes comprised in the vaccine. However, inclusion of protein antigens from *Streptococcus pneumoniae* combined with potent adjuvants and a suitable delivery system are expected to both extend protection to serotype strains not represented in the formulation and stimulate a broader immune response, thus more effective in young children, elderly, and immunocompromised populations. Along this line, nanoparticle (NP) delivery systems can enhance the immunogenicity of antigens by protecting them from degradation and increasing their uptake by antigen-presenting cells, as well as offering co-delivery with adjuvants. We report herein the encapsulation of a semisynthetic glycoconjugate (GC) composed of a synthetic tetrasaccharide mimicking the *S. pneumoniae* serotype 14 capsular polysaccharide (CP14) linked to the Pneumococcal surface protein A (PsaA) using chitosan NPs (CNPs). These GC-loaded chitosan nanoparticles (GC-CNPs) were not toxic to human monocyte-derived dendritic cells (MoDCs), showed enhanced uptake, and displayed better immunostimulatory properties in comparison to the naked GC. A comparative study was carried out in mice to evaluate the immune response elicited by the glycoconjugate-administered subcutaneously (SC), where the GC-CNPs displayed 100-fold higher IgG response as compared with the group treated with nonencapsulated GC. Overall, the study demonstrates the potential of this chitosan-based nanovaccine for efficient delivery of glycoconjugate antigens.



INTRODUCTION

Streptococcus pneumoniae is the leading cause of mortality in children under the age of 5 years. Pneumonia is responsible for 14% of all deaths in children under the age of five, killing 740,180 children in 2019. There are more than 96 serotypes of *S. pneumoniae* based on the diversity of capsular polysaccharides.¹ The first vaccines employed in the prevention of pneumococcal infection are based on these capsular polysaccharides. The introduction of conjugate vaccines has significantly reduced the global burden of pneumococcal infections across many communities.² Pneumococcal polysaccharide vaccines (PPSV23) and pneumococcal conjugate vaccines (PCV7 and PCV13) are now widely used in the clinic. Nonetheless, conjugate vaccines protect against limited serotypes whose polysaccharide components are incorporated in the vaccines. As a result, immunizing with the currently existing vaccines fails to offer protection against *S. pneumoniae* infections caused by those serotypes that are not included in the formulations. Polysaccharide or conjugate vaccines require complex manufacturing, purification, and dose optimization steps. In addition, the introduction of further serotypes in the formulations may result in an escalation of the vaccine costs. To circumvent these limitations, vaccines based on pneumococcal proteins have been investigated. Proteins like pneumococcal surface adhesin A (PsaA),^{3–5} pneumococcal

surface protein A,⁶ pneumolysin,⁷ pneumococcal histidine triad D,⁸ and ATP-binding cassette transporter lipoprotein PiuA⁹ have been extensively studied as potential vaccine components active against pneumococcal infections as they are expected to provide Th17 cellular immunity.^{10,11} The combination of protein and sugar components has been proposed to induce an additive or synergistic effect.¹² Along this line, we reported a semisynthetic glycoconjugate vaccine where PsaA plays a dual role both as an immunogen and as a carrier. PsaA was covalently linked to a synthetic tetrasaccharide (Pn14TS) to obtain a glycoconjugate (GC), characterized by a 5.4 Pn14TS/PsaA molar ratio on average.¹³ Pn14TS is a synthetic tetrasaccharide {Galβ(1 → 4)Glcβ(1 → 6)[Galβ(1 → 4)]GlcNAc} derived from the capsular polysaccharide of *S. pneumoniae* serotype 14, which is able to evoke an opsonophagocytic response.¹⁴ PsaA is a highly conserved, 37 kDa protein that is commonly present in all the 96 serotypes of *S. pneumoniae*.¹⁵ It is a member of the ATP-binding cassette

Received: June 5, 2023

Revised: August 15, 2023




Figure 1. Schematic representation of CNP preparation by the ionic gelation method.

protein that transports manganese, which is essential for virulence. Additionally, PsaA is surface-exposed, playing a significant role in the adhesion and colonization of *S. pneumoniae*.^{15,16} This makes PsaA an ideal candidate for vaccination against pneumococcal infections.^{17,18}

While most subunit vaccines alone are poor immunogens that fail to elicit T- and B-cell responses, glycoconjugate vaccines can induce better immune protection. Nevertheless, their co-administration with an adjuvant like alum, cholera toxin,^{19,20} and α -galactosylceramide (α -GalCer)²¹ can further enhance the immune response. The α -GalCer adjuvant used in this study is a glycosphingolipid that can potentially activate the NKT cells²² and has been explored as an adjuvant in both systemic and mucosal immunizations.^{23–25} As a complementary strategy, the use of particulate carriers offers multiple benefits as a vaccine delivery system: (i) they tend to mimic the pathogens with their size, shape, and often by carrying the antigens at the surface; (ii) they can act as an adjuvant; (iii) they enhance the stability of antigens; and (iv) they reduce the need of administering multiple doses.^{26–30} Several particulate systems like polymeric nanoparticles (NPs),^{31,32} metallic NPs,³³ liposomes,³⁴ and microparticles³⁵ have been explored for the delivery of pneumococcal antigens. Polymers like chitosan, alginate, protamine, dextran, hyaluronic acid, and poly(lactic-co-glycolic acid) have been investigated for protein/peptide³⁶ or DNA-based vaccines.³⁷ Among them, chitosan is a nontoxic, biocompatible, biodegradable, and mucoadhesive natural polymer, which is considered as an excellent biomaterial for the design of antigen carriers.³⁸ As an immune adjuvant, chitosan is known to enhance humoral and cellular immunity.³⁹ Despite its positive attributes, limitations such as burst release, poor mechanical properties, and stability in biological media pose a stiff challenge to its universal acceptability as a drug carrier.⁴⁰ However, the previously mentioned positive features of CNPs dominate its shortcomings. Therefore, these properties fostered researchers to adopt chitosan nanoparticles (CNPs) as a carrier for vaccine delivery.

The preparation of CNPs involves a solvent-free and simple ionic gelation method,³⁶ which makes them ideal for encapsulating delicate macromolecules like protein-based antigens. In this study, GC was encapsulated into CNPs to produce GC-CNPs, and the characterization of the resulting GC-CNPs was performed. The uptake of GC-CNPs by human dendritic cells (DCs) was studied *in vitro*. To further demonstrate the applicability of CNPs as a potential antigen carrier, their ability to induce the upregulation of costimulatory

markers related to the DC stimulation was also evaluated. Finally, a comparison of GC and GC-CNPs was carried out *in vivo*, in order to determine the role of nanoencapsulation in enhancing the immunogenicity of the glycoconjugates.

RESULTS

NP Preparation and Characterization. CNPs were prepared from chitosan (80–95% deacetylation, 30–400 kDa), poloxamer 188, and sodium tripolyphosphate in the presence or absence of GC¹³ by the ionic gelation technique that was previously developed by our group (Figure 1).³⁶ The incorporation of poloxamer in the formulation and the use of glycerol bed during NP separation are attributed for its ability to maintain the stability of the NPs⁴¹ and improve the *in vivo* efficiency of the NPs.^{42,43}

DLS analysis of GC-CNP suspensions revealed the formation of NPs with an average diameter of 142 ± 18 nm and a zeta potential of $+27 \pm 3$ mV. The PDI of the GC-CNPs was lower than 0.2, indicating the homogeneity of the NP population (Figure 2A). These values were very similar to those determined for blank CNPs, indicating an average diameter of 137 ± 21 nm and a zeta potential of $+26 \pm 2$ mV.

NP tracking analysis (NTA) displayed that the blank CNPs and GC-CNPs had a similar average particle size of around 150 nm (Figure 2B), values close to those obtained previously by DLS. The results from scanning electron microscopy confirmed that the CNPs and GC-CNPs have narrow size distribution (Figure 2C). The SEM micrographs show that CNPs presented a near-spherical morphology and showed no signs of aggregation. The diameter of a hundred particles was measured from the micrographs of both the blank CNPs and GC-CNPs (Figure 2D). The average particle size was 147 ± 19 and 145 ± 28 nm for the blank CNP and GC-CNPs, respectively. No significant difference in the distribution pattern of the NPs was observed, even though the GC-CNPs had a slightly higher number of particles in the size range below 100 nm.

The encapsulation efficiency (EE) of GC in the CNPs was found to be $70 \pm 3\%$ that corresponds to $35 \mu\text{g}$ of protein per milligram of NPs, while the EE of PsaA used for comparison was $<20\%$. When compared to PsaA, most of the amino groups of the lysine side chains were derivatized with acetyl thioacetate molecules or conjugated to Pn14TS. The higher encapsulation of GC into the NPs, when compared to PsaA, might be attributed to the diminution of surface-exposed positive charges. The prepared GC-CNPs contained approximately 6000 GCs per particle as calculated with particle




Figure 2. Particle size determination by Zetasizer, NP tracking analysis (NTA), and field emission scanning electron microscopy (FESEM) of the blank CNPs and GC-CNPs. (A) Particle size and zeta potential; (B) particle size distribution and the NP concentration of the blank and GC-CNPs, determined by NTA; (C) surface morphology of the blank CNPs and GC-CNPs determined by FESEM and shows that CNPs had a spherical shape; and (D) particle size distribution from the FESEM images calculated using ImageJ software.




Figure 3. CNP cytotoxicity on iDCs. (A) MTS staining assay and (B) 7-AAD assay was performed for both GC-CNPs (blue lines) and blank CNPs (red lines). Results are presented as mean \pm SD ($n = 4$). All the components used in the preparation of CNPs were assayed for the detection of endotoxin activity using the end-point chromogenic limulus amoebocyte assay (LAL test) (Supporting Information and Figure S2).

numbers measured by NP tracking analysis ($\sim 1.9 \times 10^{10}$ particles per mg of GC-CNPs). The NPs freeze-dried in the absence of a cryoprotectant were redispersible in water but showed an increase in particle size. Both the blank and GC-CNPs freeze-dried in the presence of 5 and 10% trehalose as a cryoprotectant were easily re-dispersible after 1 week of storage at 4 °C. This facilitates the storage of nanovaccines in a dry powder form.

In Vitro Evaluation of Dendritic Cell Viability in the Presence of CNPs. To study the influence of the GC-CNP concentration on the metabolic activity and/or survival of iDC, the MTS assay was performed to determine the cell survival in combination with metabolic activity. As can be seen in Figure 3A, over 80% of the immature dendritic cells (iDCs) were metabolically active when treated with GC-CNPs in the concentration range of 25–100 $\mu\text{g}/\text{mL}$, whereas the metabolic activity was reduced to 60% in the concentration range of 200–400 $\mu\text{g}/\text{mL}$ and significantly reduced to 40% when treated with 900 $\mu\text{g}/\text{mL}$ GC-CNPs. The results suggest that the GC-CNPs at a concentration of 25–100 $\mu\text{g}/\text{mL}$ were in the acceptable nontoxic range. The toxicity seen at the higher concentrations might be due to the possibility of the NP aggregation at higher concentrations after 12 h. However, to mitigate the risk of the NP aggregation, the CNPs were used in the concentrations of 0.1 mg/mL or lower. In this regard, the GC-CNPs at a concentration of 50 $\mu\text{g}/\text{mL}$ were adopted for further studies. In a likely manner, the cytocompatibility of the NPs with DCs was studied using the 7-AAD assay. The dose-dependent mortality of the DCs is observed in Figure 3B. The GC-CNPs at the concentration range of 25–200 $\mu\text{g}/\text{mL}$ display over 90% survival and 80% at 400 $\mu\text{g}/\text{mL}$. At the highest concentration of 900 $\mu\text{g}/\text{mL}$, the DCs displayed 75% survival (see also Figure S1 for representative histograms). However, the mortality of the DCs was not more than 25% in any case. Both the blank CNPs and GC-CNPs had a similar profile of cytocompatibility and considered to be least toxic to DCs at concentrations below 200 $\mu\text{g}/\text{mL}$.

GC-CNPs Are Effectively Internalized by iDCs. In Figure 4, from the micrographs obtained from FEG-SEM, the uptake of GC-CNPs by the iDCs can be observed upon 0.5 h of co-incubation. During the sample preparation for imaging, the iDCs undergo a series of washings to retain only the GC-CNPs firmly attached to the cell membrane, and this helps in the visualization of the NPs that are being internalized by the iDCs and not the NPs that are simply adsorbed to the cell surface. The red arrow marks in Figure 4B indicate the NPs that are being internalized by iDCs. This can be verified by comparing the captured image with the untreated iDCs shown in Figure 4A. Furthermore, the size of the internalized particles




Figure 4. Assessment of GC-CNP uptake by monocytes using FEG-SEM. (A) Untreated iDCs and (B) iDCs treated with GC-CNPs. The GC-CNPs are pointed with the red arrow marks.

indicated in red arrows aligns with the size of the GC-CNPs, as determined by DLS and NTA.

Next the uptake of GC-CNPs in DCs was studied as the function of incubation time at different temperatures. The images in Figure 5 show that the internalization of the GC-CNPs increased with time. Each red dot in Figure 5 represents a NP that is present in the plane (0.5 μm thick) of the MoDC. Even though there is a gradual increase in the NP uptake with the time until 4 h, it was not maximum, and significantly higher NPs inside the cells were observed after 24 h (Figure 6). The images correspond to a cross-section of the MoDCs, measuring $\sim 0.5 \mu\text{m}$ in thickness. Consequently, the presence of NPs in these images is located in a limited region within the cell. The uptake of the CNPs was strictly temperature dependent. The NPs were rapidly internalized at 37 °C, while the DCs incubated at 4 °C displayed only a small number of NPs in the cells, and those were mostly present on the surface of the DCs. These results are in agreement with the studies on murine DC2.4 cell lines using super-resolution microscopy or DCs using flow cytometry and confocal microscopy (see the Supporting Information and Figures S3–S5).

CNPs Enhance the Expression of the Co-stimulatory Molecules CD80 and CD86 on DCs. The study on the expression of co-stimulatory markers was carried out to elucidate the effect of GC-CNPs on DC maturation. The co-stimulatory marker CD86 is known to be a marker of primary DC maturation, while CD80 only increases in mature DCs. Many studies have shown that antigen delivery to DCs




Figure 5. Internalization of Cy5-GC-CNPs ($50 \mu\text{g}/\text{million cells}$) by iDCs at different time points (0.5, 1, 2, and 4 h). The cell membrane is stained with wheat germ agglutinin-488 (WGA-488; green color), the nucleus stained with DAPI (blue color), and the NPs are labeled with Cy5 (red color).




Figure 6. Internalization of the Cy5-GC-CNPs ($50 \mu\text{g}/\text{million cells}$) by MoDCs at 24 h (at 37 and 4 °C). The cell membrane is stained with wheat germ agglutinin-488 (WGA-488; green color), the nucleus stained with DAPI (blue color), and the NPs are labeled with Cy5 (red color).

upregulates the expression of both CD80 and CD86 that are known to induce T-cell receptor signaling and promote T-cell activation.⁴⁴ CD83 is most characteristic of cell surface markers for fully matured DCs, whose role is regulating the maturation of B and T lymphocytes.⁴⁵

As illustrated in Figure 7, iDCs treated with blank CNPs and GC-CNPs showed an enhanced expression of CD80, CD83,

and CD86 markers, although this upregulation does not reach statistical significance, probably due to the natural inter-individual variability seen among the different donors. This phenomenon is frequently observed when using monocyte-derived dendritic cells and generally allows the indication of tendencies rather than statistically significant differences. Overall, there was no marked increase in the HLA expression




Figure 7. GC-CNPs induce iDC activation and maturation. The bars in the different colors indicate GC (blue), blank CNPs (red), GC-CNPs (green), and the control with LPS + $\text{INF-}\gamma$ treatment (purple). The data represent the mean \pm SD ($n = 4$).




Figure 8. Antibody response in the mice immunized with PBS, GC, and GC-CNPs 2 weeks after the final immunization. The immunization was performed twice at days 0 and 14 and the serum antibody response in the mice was determined at day 21. The obtained results are represented as anti-PsaA IgG response (A) and anti-CP14 IgG response (B). Statistical difference between the groups is $*P < 0.01$, $**P < 0.001$, and $***P < 0.0005$. Data represent mean \pm SD ($n = 6$).

with the same treatments, probably due to the high expression level already seen in untreated iDCs.

The stimulation of DCs with different concentrations of NPs showed that the upregulation and expression of CD86 occurred in a concentration-dependent manner and was highest at 100 $\mu\text{g/mL}$ concentration. The CD80 upregulation was observed only at 100 $\mu\text{g/mL}$ and not at the lower concentrations. The CD83 upregulation was observed when treated with NPs and was independent of their concentration. The DCs treated with blank CNPs and GC-CNPs displayed a similar profile of activation marker expression, but the

upregulation was always higher in the case of GC-CNPs. This suggests that the presence of GC in the CNPs potentiates the stimulation of CD80, CD83, and CD86 by the DCs. The DCs treated with the GC alone showed similar CD83, lower CD86, and no CD80 upregulation when compared to the GC-CNP-treated DCs. Finally, a clear upregulation of all co-stimulatory molecules can be seen when iDCs were treated with LPS and $\text{INF-}\gamma$ (Figure 7, violet columns) and higher for both CD83 and CD86 when compared to CNP-treated DCs but not for CD80.

These results can emphasize the role of CNPs as an adjuvant in DC stimulation. Chitosan is known for its role in macrophage activation and upregulation of the cytokines. There were low levels of endotoxin detected in our formulations (see Figure S1), and therefore, the obtained results are not due to endotoxin-derived activation. Overall, the results suggest that the NPs alone or in combination with GC can upregulate the co-stimulatory markers in comparison to the GC alone, indicating the adjuvant property of the CNPs.

Effect of Nanoencapsulation on GC Immunogenicity.

Groups of six mice were immunized twice at 2 week interval with GC, GC-CNP, or PBS adjuvanted with α -GalCer, and induced responses were analyzed by ELISA 1 week after the second immunization. The serum analysis shows no IgM response in any groups (data not shown). The secondary sera of mice immunized with blank CNPs do not show any anti-PsaA or anti-CP14 IgG response. Both anti-mPsaA and anti-CP14 Ab responses were low in the sera of mice immunized with GC, confirming our observations when using 3 μ g of Pn14TS/dose.¹³ In contrast with these results, anti-mPsaA and anti-CP14 IgG responses were high when GC-CNPs were used as the immunogen. Anti-mPsaA and anti-CP14 were at least 100-fold higher and 10-fold higher, respectively, for the GC-CNP-treated mice in comparison to the GC-treated mice ($P < 0.0005$ and $P < 0.05$, respectively) (Figure 8).

In addition, further studies were performed to determine which subclass of IgG was predominantly expressed in the groups immunized with GC-CNPs. The serum samples of mice immunized with GC-CNPs displayed a high level of Abs of the IgG1 subclass and at a much lower extent of IgG2b against both PsaA and CP14 (Figure 9). There was no activation of




Figure 9. Subclass of anti-IgG antibody response in mice immunized with GC-CNPs 2 weeks after the final immunization. The immunization was performed twice at days 0 and 14, and the serum antibody response in the mice was determined at day 21. The obtained results are represented as anti-mPsaA IgG subclass response (A) and anti-CP IgG subclass response (B). Statistical difference between the groups is * $P < 0.05$, ** $P < 0.01$, and *** $P < 0.001$. Data represent mean \pm SD ($n = 6$).

other IgG subclasses, in particular of the IgG2a one. However, IgG2b was the second predominant IgG subclass that was in the mice immunized with GC-CNPs.

In Vivo Assay of the Protective Effect of GC and GC-CNPs. Antibody response is important in the control of *S. pneumoniae* in vivo.⁴⁶ To evaluate the efficacy of the GC-CNP formulation, we settled a model of pneumococcal infection in the mouse model. As *S. pneumoniae* serotype 14 is rapidly cleared in the mouse system, we embarked in a model of pneumococcal infection post-influenza. In this system, bacterial infection develops, and mice die from superinfection. Mice

were immunized with GC, GC-CNPs, or PBS adjuvanted with α -GalCer. Treatment with α -GalCer has been shown to be associated with lower bacterial outgrowth in superinfected animals probably linked to an unspecific innate immune response stimulation.⁴⁷ Mice were intranasally infected with a sub-lethal dose of IAV/Scotland/20/74 (H3N2) and challenged at 7 days post-influenza (dpi) with *S. pneumoniae* serotype 14. The invasive pneumococcal challenge (Figure 10)




Figure 10. Survival of vaccinated mice. Mice were challenged IN by administering 30 cfu (colony forming units) of H₃N₂, followed by 1×10^6 of *S. pneumoniae* serotype 14. The survival of the mice was monitored for 20 days. The differences between survival rates of six mice per group were analyzed by the Kaplan–Meier survival curve. Log-rank (Mantel–Cox) test $P = 0.0714$, no significant difference ($N = 1$).

in the mice displayed 50% of survival on day 20 in the group immunized with SC or GC-CNPs, while the group immunized with an equivalent amount of GC showed only 17% survival. Notably, there was 100% survival until day 13 in the mice treated with GC-CNPs, whereas the survival reduced to 50% on day 10 in the groups treated with GC. Significant protection was also observed in the group of mice which received α -GalCer in PBS only. Overall, the results demonstrated that the mice immunized with GC-CNPs exhibited higher protection against the invasive pneumococcal challenge than GCs.

DISCUSSION

CNPs (CNPs) have earlier been investigated as a carrier for numerous vaccines,^{37,48,49} including pneumococcal protein vaccines,³¹ and have been tested as an adjuvant in a mixture with PCV13.⁵⁰ To the best of our knowledge, chitosan or any other polymeric NPs have never been used as a carrier for the delivery of pneumococcal conjugate vaccines. The knowledge on the influence of the nanocarriers on the immunogenicity of the glycoconjugate is still missing.

CNPs have a proven track record in the delivery of therapeutic proteins and vaccines via a mucosal route.^{51–53} In addition, the CNPs have demonstrated to possess adjuvant activity in immunization and thus also appear as promising carriers for systemic administration.^{54,55} CNPs have the advantage of mild and solvent-free preparation that is ideal for preserving protein integrity during the encapsulation step. The incorporation of poloxamer 188 in the formulation enhances its stability⁴¹ and prevents the aggregation of the NPs during freeze-drying.⁵⁶ The NPs freeze-dried in the presence of cryoprotectants did not show any increase in the hydrodynamic diameter of the NPs after re-dispersing. This helps in long-term storage of the NPs in the powder form. In addition,

the presence of the cryoprotectant is known to protect protein conformation and structural integrity.⁵⁷

The NPs used in our studies, both blank and antigen-loaded NPs, produced low levels of toxicity and were free from endotoxin contamination. The cell viability was more than 80% at concentrations below 100 $\mu\text{g}/\text{mL}$. This was confirmed by both MTS and 7 AAD assays. Performing both MTS and 7-AAD assays helps to know the number of cells that are metabolically active vs nonapoptotic. A similar study was performed by Das et al.⁵⁸ to determine the survival of DCs in the presence of CNPs. They reported that the percentage DC survival when incubated with 100 $\mu\text{g}/\text{mL}$ CNPs was $\sim 40\%$ viability, while in our case, the viability was $>80\%$ at the same concentration. However, those CNPs had a size >250 nm and a zeta potential of $+39$ mV. It is possible that this higher zeta potential might have resulted in the increased toxicity.

The results obtained from super-resolution microscopy and flow cytometry suggest that the GC-CNPs are taken up through active pathways since the internalization does not take place at 4 °C. The imaging shows that the GC-CNPs are progressively taken up to localizing in the cytoplasm. As a result of the uptake, we found that both blank CNPs and GC-CNPs but not GC alone were able to promote the expression of costimulatory markers like CD80, CD83, and CD86. Contrasting with these results, Han et al. reported an upregulation of costimulatory markers like CD80, MHC II, and CD86 only for the antigen-loaded CNPs in comparison to the antigen alone or blank CNPs.⁵⁹ However, Franco-Molina et al. demonstrated CD80 and CD83 upregulation with blank CNPs and the differentiation of human monocytes into iDCs.⁶⁰ Thiele et al. reported that upregulation of CD83 is associated with the NP uptake by phagocytosis, which supports our results that show GC-CNP uptake by phagocytosis.⁶¹

The present study aimed to evaluate the immunogenicity of the pneumococcal glycoconjugate, whether naked or encapsulated, when SC was administered in mice. GC was poorly immunogenic in mice when administered SC in comparison with our previous experiments (Figure 8).¹³ However, in the present study, GC was administered at a 6 time lower dose. The groups immunized with GC-CNPs displayed 10- and 100-folds greater anti-CP14 and anti-PsaA IgG response, respectively, in comparison to GC (Figure 8). Strikingly, the IgG response induced by the GC-CNPs in mice was also higher than that previously observed for GC administered at a 6 time higher dose.¹³ This is in agreement with previously published results where the encapsulation of the antigen in the CNPs led to a 10-fold antigen dose reduction without affecting the level of the immune response.^{62,63} The IgG antibodies generated by GC-CNPs were predominantly IgG1 subclass. In the literature, it can be seen that the IgG1 subclass of antibodies is mainly induced by bacterial proteins, while the IgG2 antibodies are induced by capsular polysaccharides.⁶⁴ The results obtained from our studies showed greater IgG1 production against both PsaA and CP, while no IgG2a or IgG3 response was observed. Similar results were observed by Bal et al. when antigen-loaded trimethyl CNPs were injected intradermally.⁵⁵ The mice treated with GC-CNPs also displayed CP14-specific IgG1 response; this is classically ascribed to the conjugation of the carbohydrate hapten, herein Pn14TS, to the carrier protein, herein mPsaA. Interestingly, IgG2b against CP14 was the second prevalent subtype. The results are in agreement with the studies performed by González-Miro et al., where the mice immunized with self-

assembled PsaA particles produced predominantly IgG1 and IgG2b as a second predominant response.⁶⁵ The generation of anti-IgG1 Abs against both PsaA and CP can be attributed to the activation of the phagocytic response.⁶⁵ The generation of IgG1 subclass antibodies corresponds to the Th2 (humoral) immune response, and the IgG2b subclass is identified as a part of Th1 (cell-mediated) immune response.^{65,66} The results are in agreement with the hypothesis that a vaccine based on PsaA can elicit both humoral and cellular immune response.⁶⁷ Next, the functionality of Abs induced in mice was assessed using an IAV infection challenge. The mice immunized with GC-CNPs displayed greater protection over its counterparts immunized with GC.

CONCLUSIONS

In this study, we reported CNPs as a potential carrier for a semisynthetic glycoconjugate antigen. The NPs were rationally designed to encapsulate, control the release of the antigen, and maintain the stability in biological media. Moreover, the NPs could be easily freeze-dried and reconstituted, indicating the possibility for the development of a thermostable dry powder formulation. NPs were highly internalized by the dendritic cells, and the uptake was increasing with the time. Encapsulation of GC in the CNPs enhanced the expression of co-stimulatory markers when compared to the naked GC or blank CNPs. Overall, this study revealed that CNPs can enhance the immunological properties of both pneumococcal protein and carbohydrate components of the glycoconjugate vaccine, encouraging the further study of the formulation as nanoparticulate vaccine delivery systems for preventing the infections against *S. pneumoniae*.

EXPERIMENTAL SECTION

Reagents. Chitosan, poloxamer 188, and sodium tripolyphosphate were purchased from HMC⁺, Sigma-Aldrich, and BSAF, respectively. The cytokines IL-4, GM-CSF, and INF- γ were procured from Miltenyi Biotech. PBS (pH 7.2), RPMI 1640, PSG 100X, and fetal bovine serum (FBS) were obtained from Gibco, Life Technologies. Ficoll Histopaque 1077, paraformaldehyde, DAPI, Triton X-100, and pentasodium tripolyphosphate were procured from Sigma-Aldrich. All the antibodies used for FACS analysis were obtained from either Miltenyi Biotech or Sigma-Aldrich. The Pierce Chromogenic Endotoxin Quant Kit (A39552) was procured from Thermo Fisher Scientific. Cy5-NHS was purchased from Lumiprobe. The gel filtration columns (Centriprep PD10 columns) were obtained from EMP Biotech. PsaA and GC were produced in US2B at Nantes Université.¹⁴ All the other chemicals and reagents used were of analytical grade.

Preparation and Characterization of CNPs. First, 0.5 mL of chitosan solution (2 mg/mL) and 0.5 mL of poloxamer solution (20 mg/mL) in ultrapure H₂O were mixed under magnetic stirring. Next, 0.5 mL of TPP solution (0.4 mg/mL) in ultrapure H₂O was added at once to the mixture of chitosan and poloxamer under magnetic stirring (700 rpm). After 30 min of the reaction, the NPs were concentrated by centrifugation at 12,000 RCF, for 12 min, at 15 °C, using 10 μL of glycerol bed. After the centrifugation, the pellet in the bottom was carefully collected and resuspended in ultrapure water. For GC-loaded CNPs, the TPP solution (0.5 mL of 0.4 mg/mL) containing GC (50 μg) was added to 1 mL of 0.1%

w/v chitosan in 1% poloxamer kept under magnetic stirring at 700 rpm.

The particle size and polydispersity index of the NPs were measured by dynamic light scattering (DLS), and the zeta potential was calculated from the electrophoretic mobility values obtained by laser Doppler anemometry using a Zetasizer Nano-ZS90 (Malvern Instruments; Malvern, UK). All the measurements were performed at 25 °C with a detection angle of 173° in distilled water unless otherwise indicated. The NP concentration and stability in cell culture medium was evaluated by NP tracking analysis using NanoSight NS500 (Malvern Instruments; Malvern, UK). The surface morphology of the GC-CNPs was examined by field emission scanning electron microscopy (FESEM, ZEISS FESEM ULTRA Plus, Germany). For FESEM studies, 10 μ L of the GC-CNP suspension (10,000 times diluted) was placed on the silicon wafer and left to dry overnight in the desiccator. Prior to the analysis, the samples were sputter-coated with iridium (10 nm thickness). For the morphological analysis by STEM, 10 μ L of the GC-CNP suspension (10,000 times diluted) was deposited on the copper grid, stained with 2% phosphotungstic acid, and washed with ultrapure water, and the grids were left to dry overnight in the desiccator. The blank and GC-CNPs (0.5 and 1% w/v) were lyophilized in the presence of 5 and 10% (w/v) trehalose as a cryoprotectant. The samples were frozen overnight at -20 °C and then transferred to the freeze-dryer Genesis 25 ES, VirTis Model-Wizard 2.0 (SP Industries, USA). The primary drying step lasted for 35 h during which the temperature was gradually increased from -40 to -20 °C. This was followed by a secondary drying step in which the temperature was increased to RT from 0 °C. After the freeze-drying, the nanoparticles were resuspended in ultrapure water and analyzed for their particle size and PDI. A similar freeze-drying process was used to determine the formulation process yield.

Encapsulation of GC into CNPs and Release Studies.

The EE of GC in CNPs was determined by calculating the amount of free GC present in the collected supernatant after the centrifugation. The amount of free GC was determined using the micro-BCA assay kit (Thermo Fisher Scientific) by measuring the absorbance at 562 nm. The quantification was performed using the linear standard curve produced with the solutions of GC solubilized in the supernatant of CNPs in the concentration range of 0.5–10 μ g/mL. The % EE is calculated as follows: % EE = $A - B/A \times 100$, where A is the total GC and B is the free GC in the supernatant.

Fluorescence Labeling of Chitosan. The Cy5-labeled GC-CNPs were prepared to visualize the GC-CNPs during cell studies. Briefly, chitosan (50 mg; 0.3 mmol monomer units; 1 equiv) was placed in a reaction vial and dissolved in deionized water (5 mL). Cyanine (Cy5) (1 mg; 0.015 mmol; 0.050 equiv) in dimethyl sulfoxide (DMSO) (0.3 mL) was added to the chitosan solution under continuous stirring. After sealing, the vial was stirred at RT for 16 h and protected from light. After the reaction, the labeled chitosan was purified using PD10 columns (Centri Pure P10; Zetadex Gel Filtration columns). The yield of the reaction was measured afterward by weighing the freeze-dried product in the Eppendorf and subtracting the weights. The labeling of the GC-CNPs was simply performed by substituting 2% of chitosan with the Cy5-labeled chitosan (Cy5-chitosan) during the synthesis of the CNPs. Particle size analysis shows that the Cy5-GC-CNPs had an average diameter of 150 ± 9 nm and a zeta potential of 30

± 2 mV. The formulation contained approximately ~ 8 –15 thousand Cy5 molecules per particle as calculated from particle numbers obtained by NTA.

Donor Selection and Blood Collection. Buffy coats used in the experiments were obtained from anonymous donors and were kindly donated by the Agency for the Donation of Organs and Blood (ADOS, Santiago de Compostela) with the approval of the Director of the Agency and the Clinical Research Ethics Committee of Galicia (2014/543). Freshly obtained buffy coats were used within 24 h. Heparinized blood samples were obtained from healthy volunteers among the staff of Faculty of Pharmacy, University of Santiago de Compostela, and CiMUS. Before the collection, informed consent was obtained from the volunteers in accordance with the guidelines of the Ethical Committee of Clinical Research of Galicia.

DC Generation. Peripheral blood mononuclear cells (PBMCs) were isolated by the Ficoll gradient centrifugation method. Adherent monocytes were isolated by incubating PBMCs in culture plates (2 h, 37 °C) in R2 culture media (RPMI-1640 completed with 2% of FBS). After the incubation period, nonadherent cells were washed thrice with PBS, and adherent monocytes were cultured for 6 days in R10 media (RPMI-1640 completed with 10% FBS) supplemented with GM-CSF and IL-4 (100 ng/mL each). After 3 days, half of the media was replaced with fresh R10 supplemented with equal amounts of cytokines. The resultant immature DCs (iDCs) were scraped and collected from the culture plates on day 6. These iDCs were used for further experimentation. Mature DCs (mDCs) were obtained by incubation of iDCs with bacterial lipopolysaccharide (LPS) (10 ng/mL) and interferon- γ (IFN- γ) (100 U/mL) for 48 h. Murine DC2.4 cells were cultured in RPMI 1640 medium, which was supplemented with 10% fetal bovine serum and penicillin/streptomycin antibiotics.

Cytocompatibility Studies. The cytocompatibility assay of GC-CNPs in the DCs was performed by the MTS assay. The generated iDCs (1×10^5 cells/mL) were incubated with different concentrations of the CNPs (25, 50, 100, 200, 400, and 900 μ g/mL) for 24 h. The untreated iDCs were used as a positive control. After 24 h of incubation with the CNPs, the cells were washed with PBS and were incubated with fresh R10 media for another period of 24 h, and 20 μ L of MTS reagent was added to each well after 20 h and incubated for another 4 h. The intensity of the color was quantified by measuring the absorbance at 490 nm using a spectrophotometer. The results were plotted as percentage (%) viability vs the NP concentration. The percentage viability is a difference of metabolically active cells in the untreated group and the groups treated with the NPs.

The cytocompatibility of blank CNPs and GC-CNPs was also studied using 7-amino actinomycin D (7-AAD). Briefly, following the incubation of iDCs with the blank CNPs or GC-CNPs (25, 50, 100, 200, 400, and 900 μ g/mL) for 24 h, cells were harvested, washed twice with PBS, and stained with 7-AAD 1 μ L per tube (0.05 μ g/ μ L) for 30 min at 4 °C. After washing three times with PBS containing 2% BSA, the cells were analyzed by flow cytometry (BD FACSCalibur cytometer). Data were analyzed using Flowing software (Cell Imaging Core, Turku Centre for Biotechnology, Finland). Data are shown as the percentage of cells viable after incubating with the different concentrations of NPs.

Internalization of NPs by DCs. The surface morphology of the macrophages incubated with the NPs (50 μ g/mL, for

0.5 h, at 37 °C) was performed using FESEM (ZEISS FESEM ULTRA Plus, Germany).

To track the NPs after internalization by dendritic cells, the NPs and the dendritic cells were labeled with two different dyes. The NPs labeled with Cy5. DCs (5×10^5 per well) were plated into a 24-well plate with 0.5 mL of R10 media. Following that, the cells were incubated with the Cy5-labeled GC-CNPs (50 μg /million cells) for different time periods (0.5, 1, 2, 4, and 24 h). After the incubation time, the DCs were washed with PBS. Afterward, the cells were fixed with 4% PFA for 15 min. To understand the position of the NPs inside cells, the plasma membrane of the MoDCs was stained with Alexa 488-labeled WGA at 0.2 $\mu\text{g}/\text{mL}$ (wheat germ agglutinin, a lectin known to bind to *N*-acetyl-D-glucosamine and sialic acid on the cell membrane), and the nucleus was stained using DAPI. The staining was performed in Lab-Tek 8 well plates for 10 min, and the DCs were washed twice with PBS after incubation. The cells were suspended in 20–30 μL of STORM buffer (160 μL of PBS + 20 μL of 50% glucose + 20 μL of β -mercaptoethanol + 2 μL of glucose oxidase) just before imaging.

Study on the Effect of GC-CNPs on DC Maturation by Phenotypic Analysis. For the phenotypic analysis, the iDCs were seeded on 24-well plates at a density of 5×10^5 cells per well 0.5 mL of R10 media. The DCs were incubated for 48 h at 37 °C in R10 with blank or GC-CNPs using LPS (10 ng/mL) as a positive control. After 48 h of incubation, the generated DCs were collected and washed twice (300g, 7 min, 4 °C) with PBS containing 0.1% BSA. DCs were resuspended in 200 μL of PBS with 1% FCS (1% PBS); of this, 100 μL of the DCs was incubated with 50 \times diluted anti-CD83-PE, anti-CD86-APC, and anti-CD1a, another 100 μL with 50 \times diluted anti-CD80-PE, anti-HLA-APC, and anti-CD1a-FITC (in all cases, for 30 min, in the dark, on ice). CD1a was included as a DC marker to verify correct monocyte differentiation. After the 30 min staining period, the cells were harvested, washed thrice with 1% PBS, and resuspended in 500 μL of PBS. The DCs were quantified for the expression of CD80, CD83, CD86, and HLA using flow cytometry (BD FACSCalibur flow cytometer; BD Biosciences, Madrid). The cytometry data were analyzed using the Flowing software program (Cell Imaging Core, Turku Centre for Biotechnology, Finland). The forward versus side scattering was used for gating the live cells, and the CD1a-positive cells were picked for the quantification of costimulatory markers. The expression of cytokines from the CNPs-treated DCs were compared against the LPS-treated DCs, assuming 100% maturation.

Immunization Studies in Mice. Specific pathogen-free C57BL/6 mice (6 weeks-old, female) were purchased from Janvier (Le Genest-St-Isle, France). Mice were maintained in a biosafety level 2 facility in the Animal Resource Centre at the Lille Pasteur Institute for at least 2 weeks prior to usage to allow appropriate acclimation. Mice were fed a standard rodent chow (SAFE A04) (SAFE, Augy, France) and water ad libitum. The diet contains \sim 11.8% fiber including \sim 10% water-insoluble fiber (3.6% cellulose) and 1.8% water-soluble fiber. All the animal experiments were performed at Lille Pasteur Institute according to the ethical guidelines (agreement number AF 16/20090 and 00357.03).

Groups of six female C57BL/6 mice were injected SC with GC or GC-CNPs (0.6 μg of carbohydrate antigen/5 μg protein/dose). All mice were administered with 250 ng of α -GalCer as an adjuvant. Three groups of mice were immunized

with SC on day 0 and boosted at day 14 with PBS, GC, or GC-CNP. Mice were bled 1 day prior the first immunization and 1 week after every immunization. Sera were stored at -80 °C until the quantification of Ab response by ELISA.

Measurement of Humoral Response. The Ab responses induced upon immunization were assessed by using enzyme-linked immunosorbent assay (ELISA) as described previously, with slight modifications. In brief, the samples with different serial dilutions were loaded into individual 96-well microtiter Nunc Maxisorp (Thermo Fisher Scientific), where the plates were coated with mPsaA (0.1 $\mu\text{g}/\text{well}$) or Pn14TS (0.2 $\mu\text{g}/\text{well}$) and plates overnight at 4 °C. The goat anti-mouse IgA, IgM, and IgG(H + L)-HRP-labeled conjugate (CliniSciences) used as secondary Ab at a dilution of 1/6000 was used as secondary antibodies. The reactions were read in an Infinite M1000 spectrophotometer (TECAN). Similarly, anti-mouse IgG1, IgG2a, IgG2b, and IgG3 were used to determine the predominant IgG subclass expressed. To determine the anti-CP14 response, the purified capsular polysaccharide (CP14) (Alliance Bio Expertise, France) was coated in the wells. The Ab titer was defined as the dilution of immune serum that gave an OD (405 nm) at least twice that observed with pre-immune serum.

Influenza A Virus Infection. The *S. pneumoniae* (serotype 14) strain used in this study was a gift from Dr M. de Jonge (Nijmegen University, The Netherlands). The mouse-adapted H3N2 IAV strain Scotland/20/1974 was described in ref 68. For infection with IAV, 50 μL of phosphate-buffered saline containing (or not, in a mock sample) 30 plaque-forming units (PFU) of the H3N2 IAV strain Scotland/20/1974 was intranasally administered to anesthetized mice. This dose corresponds to a sub-lethal dose, which is necessary to investigate secondary bacterial infection. For secondary pneumococcal infection post-influenza, mice were challenged (I.N) at 7 dpi with *S. pneumoniae* (1×10^6 PFU). The survival of the mice was monitored for 20 days.⁶⁹

Statistical Analysis. The two-way ANOVA Bonferroni's multiple comparison test, Mann–Whitney *U* test, one-way ANOVA with Kruskal–Wallis analysis by Dunn's multiple comparison test and one-way ANOVA with Bonferroni's multiple comparison test were used to calculate the statistical significance. A probability value of $P < 0.05$ was considered statistically significant.

■ ASSOCIATED CONTENT

SI Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acs.bioconjchem.3c00252>.

Representative histograms; endotoxin analysis; internalization of Cy5-GC-CNPs by DC2.4 cell lines, MoDCs, and DCs; and associated experimental part (PDF)

■ AUTHOR INFORMATION

Corresponding Authors

Cyrille Grandjean – Nantes Université, CNRS, Unité des Sciences Biologiques et des Biotechnologies (US2B), UMR 6286, Nantes F-44000, France; orcid.org/0000-0002-9775-6917; Email: cyrille.grandjean@univ-nantes.fr

Noemi Csaba – Center for Research in Molecular Medicine and Chronic Diseases, Department of Pharmacology, Pharmacy and Pharmaceutical Technology, University of Santiago de Compostela, Santiago de Compostela 15706,

Spain; orcid.org/0000-0002-6187-7717;
Email: noemi.csaba@usc.es

Authors

Maruthi Prasanna – Center for Research in Molecular Medicine and Chronic Diseases, Department of Pharmacology, Pharmacy and Pharmaceutical Technology, University of Santiago de Compostela, Santiago de Compostela 15706, Spain; Nantes Université, CNRS, Unité des Sciences Biologiques et des Biotechnologies (US2B), UMR 6286, Nantes F-44000, France; Department of Biochemistry and Molecular Biology, University of Santiago de Compostela, Santiago de Compostela 15706, Spain; Present Address: Avaxzipen Ltd, Milton Park, Abingdon, Oxfordshire, United Kingdom, OX14 4SA; orcid.org/0000-0002-0179-4215

Rubén Varela Calvino – Department of Biochemistry and Molecular Biology, University of Santiago de Compostela, Santiago de Compostela 15706, Spain

Annie Lambert – Nantes Université, CNRS, Unité des Sciences Biologiques et des Biotechnologies (US2B), UMR 6286, Nantes F-44000, France

Maria Arista Romero – Department of Biological Chemistry, Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), Barcelona 08034, Spain; orcid.org/0000-0002-1992-070X

Sylvia Pujals – Department of Biological Chemistry, Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), Barcelona 08034, Spain

François Trottein – Univ. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019—UMR 9017—CIIIL—Center for Infection and Immunity of Lille, Lille F-59000, France

Emilie Camberlein – Nantes Université, CNRS, Unité des Sciences Biologiques et des Biotechnologies (US2B), UMR 6286, Nantes F-44000, France; orcid.org/0000-0003-4364-6699

Complete contact information is available at:
<https://pubs.acs.org/10.1021/acs.bioconjchem.3c00252>

Author Contributions

This manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

This work was supported by the grant from European Commission, Education, Audiovisual and Culture Executive Agency (EACEA), under the Erasmus Mundus programme, “NanoFar: European Doctorate in Nanomedicine and Pharmaceutical Innovation” (project: 2015-01-C4). C.G. thanks COST Action CA18103: INNOGLY: INNOVation with GLYcans: new frontiers from synthesis to new biological targets. N.C. acknowledges PID2019-107500RB-I00 Ministerio de Economía y Competitividad—Spain, 2021-PG038 GRC, Xunta de Galicia-Spain. We would like to thank Dr. B.F. (University of Strasbourg) for the production of α -GalCer. M.P. thanks Cristina Calvino Sanpedro for initially teaching him how to work with human dendritic cells.

ABBREVIATIONS

α -GalCer	α -galactosyl ceramide
7-AAD	7-aminoactinomycin D
APC	allophycocyanin
DCs	dendritic cells
DLS	dynamic light scattering
DAPI	4',6-diamidino-2-phenylindole
FESEM	field emission scanning electron microscopy
GM-CSF	granulocyte-macrophage colony-stimulating factor
iDCs	immature dendritic cells
I.N	intranasal
LAL	limulus amoebocyte lysate
LPS	lipopolysaccharide
MoDCs	human monocyte-derived dendritic cells
MTS	(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)
NTA	nanoparticle tracking analysis
PCV	pneumococcal conjugate vaccine
PPSV	pneumococcal polysaccharide vaccines
S.C	subcutaneous
STORM	stochastic optical reconstruction microscopy
TPP	tripolyphosphate
WGA	wheat germ agglutinin

REFERENCES

- Geno, K. A.; Gilbert, G. L.; Song, J. Y.; Skovsted, I. C.; Klugman, K. P.; Jones, C.; Konradsen, H. B.; Nahm, M. H. Pneumococcal Capsules and Their Types: Past, Present, and Future. *Clin. Microbiol. Rev.* **2015**, *28*, 871–899.
- Torres, A.; Bonanni, P.; Hryniewicz, W.; Moutschen, M.; Reinert, R. R.; Welte, T. Pneumococcal Vaccination: What Have We Learnt so Far and What Can We Expect in the Future? *Eur. J. Clin. Microbiol. Infect. Dis.* **2014**, *34*, 19–31.
- Rajam, G.; Anderton, J. M.; Carlone, G. M.; Sampson, J. S.; Ades, E. W. Pneumococcal Surface Adhesin A (PsaA): A Review. *Crit. Rev. Microbiol.* **2008**, *34*, 131–142.
- Olafsdottir, T. A.; Lingnau, K.; Nagy, E.; Jonsdottir, I. Novel Protein-Based Pneumococcal Vaccines Administered with the Th1-Promoting Adjuvant IC31 Induce Protective Immunity against Pneumococcal Disease in Neonatal Mice. *Infect. Immun.* **2012**, *80*, 461–468.
- Rapola, S.; Jääntti, V.; Haikala, R.; Syrjänen, R.; Carlone, G. M.; Sampson, J. S.; Briles, D. E.; Paton, J. C.; Takala, A. K.; Kilpi, T. M.; Käyhty, H. Natural Development of Antibodies to Pneumococcal Surface Protein A, Pneumococcal Surface Adhesin A, and Pneumolysin in Relation to Pneumococcal Carriage and Acute Otitis Media. *J. Infect. Dis.* **2000**, *182*, 1146–1152.
- Csordas, F. C. L.; Perciani, C. T.; Darrieux, M.; Gonçalves, V. M.; Cabrera-Crespo, J.; Takagi, M.; Sbrógio-Almeida, M. E.; Leite, L. C. C.; Tanizaki, M. M. Protection Induced by Pneumococcal Surface Protein A (PspA) Is Enhanced by Conjugation to a Streptococcus Pneumoniae Capsular Polysaccharide. *Vaccine* **2008**, *26*, 2925–2929.
- Zhang, Q.; Choo, S.; Finn, A. Immune Responses to Novel Pneumococcal Proteins Pneumolysin, PspA, PsaA, and CbpA in Adenoidal B Cells from Children. *Infect. Immun.* **2002**, *70*, 5363–5369.
- Pauksens, K.; Nilsson, A. C.; Caubet, M.; Pascal, T. G.; Van Belle, P.; Poolman, J. T.; Vandepapelière, P. G.; Verlant, V.; Vink, P. E. Randomized Controlled Study of the Safety and Immunogenicity of Pneumococcal Vaccine Formulations Containing PhtD and Detoxified Pneumolysin with Alum or Adjuvant System AS02V in Elderly Adults. *Clin. Vaccine Immunol.* **2014**, *21*, 651–660.
- Reglinski, M.; Ercoli, G.; Plumtre, C.; Kay, E.; Petersen, F. C.; Paton, J. C.; Wren, B. W.; Brown, J. S. A Recombinant Conjugated Pneumococcal Vaccine That Protects against Murine Infections with a Similar Efficacy to Prevnar-13. *npj Vaccines* **2018**, *3*, 53.

- (10) Ogunniyi, A. D.; Paton, J. C. Vaccine Potential of Pneumococcal Proteins. *Streptococcus Pneumoniae* **2015**, 59–78.
- (11) Moffitt, K. L.; Malley, R. Next Generation Pneumococcal Vaccines. *Curr. Opin. Immunol.* **2011**, 23, 407–413.
- (12) Hill, A. B.; Beitelshes, M.; Nayerhoda, R.; Pfeifer, B. A.; Jones, C. H. Engineering a Next-Generation Glycoconjugate-Like Streptococcus Pneumoniae Vaccine. *ACS Infect. Dis.* **2018**, 4, 1553–1563.
- (13) Prasanna, M.; Soulard, D.; Camberlein, E.; Ruffier, N.; Lambert, A.; Trottein, F.; Csaba, N.; Grandjean, C. Semisynthetic Glycoconjugate Based on Dual Role Protein/PsaA as a Pneumococcal Vaccine. *Eur. J. Pharm. Sci.* **2019**, 129, 31–41.
- (14) Safari, D.; Dekker, H. A. T.; Joosten, J. A. F.; Michalik, D.; de Souza, A. C.; Adamo, R.; Lahmann, M.; Sundgren, A.; Oscarson, S.; Kamerling, J. P.; Snippe, H. Identification of the Smallest Structure Capable of Evoking Opsonophagocytic Antibodies against Streptococcus Pneumoniae Type 14. *Infect. Immun.* **2008**, 76, 4615–4623.
- (15) Morrison, K. E.; Lake, D.; Crook, J.; Carlone, G. M.; Ades, E.; Facklam, R.; Sampson, J. S. Confirmation of PsaA in All 90 Serotypes of Streptococcus Pneumoniae by PCR and Potential of This Assay for Identification and Diagnosis. *J. Clin. Microbiol.* **2000**, 38, 434–437.
- (16) Sampson, J. S.; Furlow, Z.; Whitney, A. M.; Williams, D.; Facklam, R.; Carlone, G. M. Limited Diversity of Streptococcus Pneumoniae PsaA among Pneumococcal Vaccine Serotypes. *Infect. Immun.* **1997**, 65, 1967–1971.
- (17) Schmid, P.; Selak, S.; Keller, M.; Luhan, B.; Magyarics, Z.; Seidel, S.; Schlick, P.; Reinisch, C.; Lingnau, K.; Nagy, E.; Grubeck-Loebenstien, B. Th17/Th1 Biased Immunity to the Pneumococcal Proteins PcsB, StkP and PsaA in Adults of Different Age. *Vaccine* **2011**, 29, 3982–3989.
- (18) Colaco, C.; Cecchini, P.; Entwisle, C.; Joachim, M.; Pang, Y.; Dalton, K.; Hill, S.; McIlgorm, A.; Chan, W.-Y.; Brown, J.; Bailey, C.; Clarke, S. Next Generation Vaccines: Development of a Novel Streptococcus Pneumoniae Multivalent Protein Vaccine. *BioProcess. J.* **2015**, 14, 18.
- (19) Shen, X.; Lagergård, T.; Yang, Y.; Lindblad, M.; Fredriksson, M.; Wallerström, G.; Holmgren, J. Effect of Pre-Existing Immunity for Systemic and Mucosal Immune Responses to Intranasal Immunization with Group B Streptococcus Type III Capsular Polysaccharide-Cholera Toxin B Subunit Conjugate. *Vaccine* **2001**, 19, 3360–3368.
- (20) Seo, J.-Y.; Seong, S. Y.; Ahn, B.-Y.; Kwon, I. C.; Chung, H.; Jeong, S. Y. Cross-Protective Immunity of Mice Induced by Oral Immunization with Pneumococcal Surface Adhesin Encapsulated in Microspheres. *Infect. Immun.* **2002**, 70, 1143–1149.
- (21) Liu, Y.; Hardie, J.; Zhang, X.; Rotello, V. M. Effects of Engineered Nanoparticles on the Innate Immune System. *Semin. Immunol.* **2017**, 34, 25–32.
- (22) Carreño, L. J.; Kharkwal, S. S.; Porcelli, S. A. Optimizing NKT Cell Ligands as Vaccine Adjuvants. *Immunotherapy* **2014**, 6, 309–320.
- (23) Ko, S.-Y.; Ko, H.-J.; Chang, W.-S.; Park, S.-H.; Kweon, M.-N.; Kang, C.-Y. α -Galactosylceramide Can Act As a Nasal Vaccine Adjuvant Inducing Protective Immune Responses against Viral Infection and Tumor. *J. Immunol.* **2005**, 175, 3309–3317.
- (24) Davitt, C. J. H.; Longet, S.; Albutti, A.; Aversa, V.; Nordqvist, S.; Hackett, B.; McEntee, C. P.; Rosa, M.; Coulter, I. S.; Lebens, M.; Tobias, J.; Holmgren, J.; Lavelle, E. C. Alpha-Galactosylceramide Enhances Mucosal Immunity to Oral Whole-Cell Cholera Vaccines. *Mucosal Immunol.* **2019**, 12, 1055–1064.
- (25) Lu, G.; Zhou, A.; Meng, M.; Wang, L.; Han, Y.; Guo, J.; Zhou, H.; Cong, H.; Zhao, Q.; Zhu, X. Q.; He, S. Alpha-Galactosylceramide Enhances Protective Immunity Induced by DNA Vaccine of the SAG5D Gene of Toxoplasma Gondii. *BMC Infect. Dis.* **2014**, 14, 3862.
- (26) Dacoba, T. G.; Olivera, A.; Torres, D.; Crecente-Campo, J.; Alonso, M. J. Modulating the Immune System through Nanotechnology. *Semin. Immunol.* **2017**, 34, 78–102.
- (27) Zaman, M.; Chandrudu, S.; Toth, I. Strategies for Intranasal Delivery of Vaccines. *Drug Delivery Transl. Res.* **2013**, 3, 100–109.
- (28) Storni, T.; Kundig, T.; Senti, G.; Johansen, P. Immunity in Response to Particulate Antigen-Delivery Systems. *Adv. Drug Delivery Rev.* **2005**, 57, 333–355.
- (29) Bernocchi, B.; Carpentier, R.; Betbeder, D. Nasal Nanovaccines. *Int. J. Pharm.* **2017**, 530, 128–138.
- (30) Csaba, N.; Garcia-Fuentes, M.; Alonso, M. J. Nanoparticles for Nasal Vaccination. *Adv. Drug Delivery Rev.* **2009**, 61, 140–157.
- (31) Xu, J.-H.; Dai, W.-J.; Chen, B.; Fan, X.-Y. Mucosal Immunization with PsaA Protein, Using Chitosan as a Delivery System, Increases Protection Against Acute Otitis Media and Invasive Infection by Streptococcus Pneumoniae. *Scand. J. Immunol.* **2015**, 81, 177–185.
- (32) Robla, S.; Prasanna, M.; Varela-Calviño, R.; Grandjean, C.; Csaba, N. A Chitosan-Based Nanosystem as Pneumococcal Vaccine Delivery Platform. *Drug Delivery Transl. Res.* **2021**, 11, 581–597.
- (33) Safari, D.; Marradi, M.; Chiodo, F.; Th Dekker, H. A.; Shan, Y.; Adamo, R.; Oscarson, S.; Rijkers, G. T.; Lahmann, M.; Kamerling, J. P.; Penadés, S.; Snippe, H. Gold Nanoparticles as Carriers for a Synthetic Streptococcus Pneumoniae Type 14 Conjugate Vaccine. *Nanomedicine* **2012**, 7, 651–662.
- (34) Tada, R.; Suzuki, H.; Takahashi, S.; Negishi, Y.; Kiyono, H.; Kunisawa, J.; Aramaki, Y. Nasal Vaccination with Pneumococcal Surface Protein A in Combination with Cationic Liposomes Consisting of DOTAP and DC-Chol Confers Antigen-Mediated Protective Immunity against Streptococcus Pneumoniae Infections in Mice. *Int. Immunopharmacol.* **2018**, 61, 385–393.
- (35) Cho, N.-H.; Seong, S.-Y.; Chun, K.-H.; Kim, Y.-H.; Chan Kwon, I.; Ahn, B.-Y.; Jeong, S. Y. Novel Mucosal Immunization with Polysaccharide-Protein Conjugates Entrapped in Alginate Microspheres. *J. Control. Release* **1998**, 53, 215–224.
- (36) Calvo, P.; Remuñan-López, C.; Vila-Jato, J. L.; Alonso, M. J. Chitosan and Chitosan/Ethylene Oxide-Propylene Oxide Block Copolymer Nanoparticles as Novel Carriers for Proteins and Vaccines. *Pharm. Res.* **1997**, 14, 1431–1436.
- (37) Csaba, N.; Köping-Höggård, M.; Alonso, M. J. Ionically Crosslinked Chitosan/Tripolyphosphate Nanoparticles for Oligonucleotide and Plasmid DNA Delivery. *Int. J. Pharm.* **2009**, 382, 205–214.
- (38) Moran, H. B. T.; Turley, J. L.; Andersson, M.; Lavelle, E. C. Immunomodulatory Properties of Chitosan Polymers. *Biomaterials* **2018**, 184, 1–9.
- (39) Zaharoff, D. A.; Rogers, C. J.; Hance, K. W.; Schlom, J.; Greiner, J. W. Chitosan Solution Enhances Both Humoral and Cell-Mediated Immune Responses to Subcutaneous Vaccination. *Vaccine* **2007**, 25, 2085–2094.
- (40) López-León, T.; Carvalho, E. L. S.; Seijo, B.; Ortega-Vinuesa, J. L.; Bastos-González, D. Physicochemical Characterization of Chitosan Nanoparticles: Electrokinetic and Stability Behavior. *J. Colloid Interface Sci.* **2005**, 283, 344–351.
- (41) Santander-Ortega, M. J.; Jódar-Reyes, A. B.; Csaba, N.; Bastos-González, D.; Ortega-Vinuesa, J. L. Colloidal Stability of Pluronic F68-Coated PLGA Nanoparticles: A Variety of Stabilisation Mechanisms. *J. Colloid Interface Sci.* **2006**, 302, 522–529.
- (42) Kang, M. L.; Jiang, H.-L.; Kang, S. G.; Guo, D. D.; Lee, D. Y.; Cho, C.-S.; Yoo, H. S. Pluronic F127 Enhances the Effect as an Adjuvant of Chitosan Microspheres in the Intranasal Delivery of Bordetella Bronchiseptica Antigens Containing Dermonecrototoxin. *Vaccine* **2007**, 25, 4602–4610.
- (43) Coeshott, C. M.; Smithson, S. L.; Verderber, E.; Samaniego, A.; Blonder, J. M.; Rosenthal, G. J.; Westerink, M. A. J. Pluronic F127-Based Systemic Vaccine Delivery Systems. *Vaccine* **2004**, 22, 2396–2405.
- (44) Al-Ashmawy, G. M. Z. Dendritic Cell Subsets, Maturation and Function. *Dendritic Cells*; InTech, 2018.
- (45) Breloer, M.; Fleischer, B. CD83 Regulates Lymphocyte Maturation, Activation and Homeostasis. *Trends Immunol.* **2008**, 29, 186–194.
- (46) Sorensen, R. U.; Edgar, J. D. M. Overview of Antibody-Mediated Immunity to S. Pneumoniae: Pneumococcal Infections,

Pneumococcal Immunity Assessment, and Recommendations for IG Product Evaluation. *Transfusion* **2018**, *58*, 3106–3113.

(47) Barthelemy, A.; Ivanov, S.; Hassane, M.; Fontaine, J.; Heurtault, B.; Frisch, B.; Faveeuw, C.; Paget, C.; Trottein, F. Exogenous Activation of Invariant Natural Killer T Cells by α -Galactosylceramide Reduces Pneumococcal Outgrowth and Dissemination Post-influenza. *mBio* **2016**, *7*, No. e01440.

(48) Amidi, M.; Romeijn, S. G.; Verhoef, J. C.; Junginger, H. E.; Bungener, L.; Huckriede, A.; Crommelin, D. J. A.; Jiskoot, W. N-Trimethyl Chitosan (TMC) Nanoparticles Loaded with Influenza Subunit Antigen for Intranasal Vaccination: Biological Properties and Immunogenicity in a Mouse Model. *Vaccine* **2007**, *25*, 144.

(49) Xu, J.; Dai, W.; Wang, Z.; Chen, B.; Li, Z.; Fan, X. Intranasal Vaccination with Chitosan-DNA Nanoparticles Expressing Pneumococcal Surface Antigen A Protects Mice against Nasopharyngeal Colonization by Streptococcus Pneumoniae. *Clin. Vaccine Immunol.* **2011**, *18*, 75–81.

(50) Haryono, A.; Salsabila, K.; Restu, W. K.; Harmami, S. B.; Safari, D. Effect of Chitosan and Liposome Nanoparticles as Adjuvant Codelivery on the Immunoglobulin G Subclass Distribution in a Mouse Model. *J. Immunol. Res.* **2017**, *2017*, 1–5.

(51) Pawar, D.; Jagannathan, K. S. Mucoadhesive Glycol Chitosan Nanoparticles for Intranasal Delivery of Hepatitis B Vaccine : Enhancement of Mucosal and Systemic Immune Response Mucoadhesive Glycol Chitosan Nanoparticles for Intranasal Delivery of Hepatitis B Vaccine : Enhancement of Muco. *Drug Delivery* **2016**, *23*, 185.

(52) Xu, W.; Shen, Y.; Jiang, Z.; Wang, Y.; Chu, Y.; Xiong, S. Intranasal Delivery of Chitosan–DNA Vaccine Generates Mucosal SIgA and Anti-CVB3 Protection. *Vaccine* **2004**, *22*, 3603.

(53) Fernández-Urrusuno, R.; Calvo, P.; Remuñán-López, C.; Vila-Jato, J. L.; José Alonso, M. Enhancement of Nasal Absorption of Insulin Using Chitosan Nanoparticles. *Pharm. Res.* **1999**, *16*, 1576–1581.

(54) Neimert-Andersson, T.; Hällgren, A. C.; Andersson, M.; Langebäck, J.; Zettergren, L.; Nilsen-Nygaard, J.; Draget, K. I.; van Hage, M.; Lindberg, A.; Gafvelin, G.; Grönlund, H. Improved Immune Responses in Mice Using the Novel Chitosan Adjuvant ViscoGel, with a Haemophilus Influenzae Type b Glycoconjugate Vaccine. *Vaccine* **2011**, *29*, 8965–8973.

(55) Bal, S. M.; Slütter, B.; Verheul, R.; Bouwstra, J. A.; Jiskoot, W. Adjuvanted, antigen loaded N-trimethyl chitosan nanoparticles for nasal and intradermal vaccination: Adjuvant- and site-dependent immunogenicity in mice. *Eur. J. Pharm. Sci.* **2012**, *45*, 475–481.

(56) Alonso, M. J.; Gupta, R. K.; Min, C.; Siber, G. R.; Langer, R. Biodegradable Microspheres as Controlled-Release Tetanus Toxoid Delivery Systems. *Vaccine* **1994**, *12*, 299–306.

(57) Nail, S. L.; Jiang, S.; Chongprasert, S.; Knopp, S. A. Fundamentals of Freeze-Drying. *Development and Manufacture of Protein Pharmaceuticals*; Springer: Boston, MA, 2002; pp 281–360.

(58) Das, I.; Padhi, A.; Mukherjee, S.; Dash, D. P.; Kar, S.; Sonawane, A. Biocompatible Chitosan Nanoparticles as an Efficient Delivery Vehicle for *Mycobacterium Tuberculosis* Lipids to Induce Potent Cytokines and Antibody Response through Activation of $\gamma\delta$ T Cells in Mice. *Nanotechnology* **2017**, *28*, 165101.

(59) Han, H. D.; Byeon, Y.; Jang, J. H.; Jeon, H. N.; Kim, G. H.; Kim, M. G.; Park, C. G.; Kang, T. H.; Jung, I. D.; Lim, Y. T.; Lee, Y. J.; Lee, J. W.; Shin, B. C.; Ahn, H. J.; Sood, A. K.; Park, Y. M. In vivo stepwise immunomodulation using chitosan nanoparticles as a platform nanotechnology for cancer immunotherapy. *Sci. Rep.* **2016**, *6*, 38348.

(60) Franco-Molina, M. A.; Coronado-Cerda, E. E.; López-Pacheco, E.; Zarate-Triviño, D. G.; Galindo-Rodríguez, S. A.; del Carmén Salazar-Rodríguez, M.; Ramos-Zayas, Y.; Tamez-Guerra, R.; Rodríguez-Padilla, C. Chitosan Nanoparticles Plus KLH Adjuvant as an Alternative for Human Dendritic Cell Differentiation. *Curr. Nanosci.* **2019**, *15*, 532–540.

(61) Thiele, L.; Rothen-Rutishauser, B.; Jilek, S.; Wunderli-Allenspach, H.; Merkle, H. P.; Walter, E. Evaluation of Particle

Uptake in Human Blood Monocyte-Derived Cells in Vitro. Does Phagocytosis Activity of Dendritic Cells Measure up with Macrophages? *J. Control. Release* **2001**, *76*, 59–71.

(62) Gordon, S.; Saupe, A.; McBurney, W.; Rades, T.; Hook, S. Comparison of Chitosan Nanoparticles and Chitosan Hydrogels for Vaccine Delivery. *J. Pharm. Pharmacol.* **2010**, *60*, 1591–1600.

(63) Bulmer, C.; Margaritis, A.; Xenocostas, A. Production and Characterization of Novel Chitosan Nanoparticles for Controlled Release of rHu-Erythropoietin. *Biochem. Eng. J.* **2012**, *68*, 61–69.

(64) Papadea, C.; Check, I. J. Human Immunoglobulin G and Immunoglobulin G Subclasses: Biochemical, Genetic, and Clinical Aspects. *Crit. Rev. Clin. Lab. Sci.* **1989**, *27*, 27–58.

(65) González-Miro, M.; Rodríguez-Noda, L.; Fariñas-Medina, M.; García-Rivera, D.; Vérez-Bencomo, V.; Rehm, B. H. A. Self-Assembled Particulate PsaA as Vaccine against Streptococcus Pneumoniae Infection. *Heliyon* **2017**, *3*, No. e00291.

(66) Vadesilho, C. F. M.; Ferreira, D. M.; Moreno, A. T.; Chavez-Olortegui, C.; Machado de Avila, R. A.; Oliveira, M. L. S.; Ho, P. L.; Miyaji, E. N. Characterization of the Antibody Response Elicited by Immunization with Pneumococcal Surface Protein A (PspA) as Recombinant Protein or DNA Vaccine and Analysis of Protection against an Intranasal Lethal Challenge with Streptococcus Pneumoniae. *Microb. Pathog.* **2012**, *53*, 243–249.

(67) Palaniappan, R.; Singh, S.; Singh, U. P.; Sakthivel, S. K. K.; Ades, E. W.; Briles, D. E.; Hollingshead, S. K.; Paton, J. C.; Sampson, J. S.; Lillard, J. W., Jr. Differential PsaA-PspA-PspC-and PdB-Specific Immune Responses in a Mouse Model of Pneumococcal Carriage. *Infect. Immun.* **2005**, *73*, 1006–1013.

(68) Paget, C.; Ivanov, S.; Fontaine, J.; Blanc, F.; Pichavant, M.; Renneson, J.; Bialecki, E.; Pothlichet, J.; Vendeville, C.; Barba-Speath, G.; Huerre, M. R.; Faveeuw, C.; Si-Tahar, M.; Trottein, F.; Trottein, F. Potential Role of Invariant NKT Cells in the Control of Pulmonary Inflammation and CD8+ T Cell Response during Acute Influenza A Virus H3N2 Pneumonia. *J. Immunol.* **2011**, *186*, 5590–5602.

(69) Kosai, K.; Seki, M.; Tanaka, A.; Morinaga, Y.; Imamura, Y.; Izumikawa, K.; Kakeya, H.; Yamamoto, Y.; Yanagihara, K.; Tomono, K.; Kohno, S. Increase of Apoptosis in a Murine Model for Severe Pneumococcal Pneumonia during Influenza A Virus Infection. *Jpn. J. Infect. Dis.* **2011**, *64*, 451–457.